A closer look at the technologies used by Epsilogen
See more technologies
Epsilogen
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
London Manbre Hammersmith Road, Waterfro...Phone Number
+44 2036577612Website
www.epsilogen.comRevenue
$11.5 MillionIndustry
About Epsilogen
Epsilogen is a pioneering company specializing in pan-isotype antibody therapeutics for cancer treatment, focusing on immunoglobulin IgE, IgA, and IgG-based therapies. Their lead product, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, targeting folate receptors in platinum-resistant ovarian cancer patients. The company aims to optimize immune responses by matching antibody isotypes to specific cancers and combining them to enhance anti-cancer potential. Epsilogen's innovative approach positions it as a leader in the development of novel cancer therapies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Epsilogen
Compare insights from companies similar to Epsilogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Epsilogen
$11.5M
11-50
Private
$67.8M
2017
N/A
Epsilogen Tech Stack
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Epsilogen
Sign Up For FreeTo access detailed company insights
Epsilogen is a pioneering company specializing in pan-isotype antibody therapeutics for cancer treatment, focusing on immunoglobulin IgE, IgA, and IgG-based therapies. Their lead product, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, targeting folate receptors in platinum-resistant ovarian cancer patients. The company aims to... Read More
